Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hi-DoRi-3: High-dose rifampicin to shorten treatment of drug-sensitive pulmonary tuberculosis
KCT0005357Phase 3Completed
- Sponsor
- Korea Disease Control and Prevention Agency
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rifampicin in pulmonary tuberculosis (TB), sponsored by Korea Disease Control and Prevention Agency. Started Nov 2020; status: completed.
02
Drugs
rifampicin
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on KCT0005357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005357.